摘要
目的：探讨孕早期唐氏综合征（DS）的产前筛查方法。方法：采用时间分辨免疫法对孕7-13周452例孕妇血清中PAPP—A和β-HCG两项血清标记物进行检测。同时用超声对其中孕10—13周的孕妇测量颈部透明带（nuchal translucency，NT）厚度。用Tl—risk风险统计软件进行风险率计算，以1：250作为高风险的切割值。结果：二联生化筛查7-13周的452例孕妇中，筛出高危孕妇45例，确诊DS胎儿1例；二联生化＋NT筛查10—13周的孕妇101例，筛出高危孕妇6例。结论：孕早期二联生化＋NT筛查DS胎儿，有望使产前诊断时间提前，且筛查结果的假阳性率降低。
Objective： To assess the effectiveness of the combined test in the prenatal detection of trisomy 21 in the first - trimester. Methods： First - trimester maternal serum biochemical markers （ PAPP - A, β - HCG） were determined in maternal serum at 7 ～ 13 weeks. Fetal nuchal translucency were assessed at 10 ～ 13 weeks by ultrasound scan. A combined risk was estimated. When the risk was 1 ： 250 or above, it was regarded as the cut -off value of high risk. Results： Biochemistry screening： in 452 pregnant women, 45 cases were screened as high risk. One was identified as DS fetus. Biochemistry ＋ NT： in 101 pregnant women, 6 cases were screened as high risk. Conclusion： Screening for DS in the first trimester is feasible. The time of screening would be earlier than before a remarkably reduced false - positive observed.
出处
《中国妇幼保健》
CAS
北大核心
2007年第3期385-387,共3页
Maternal and Child Health Care of China
基金
天津市自然科学基金资助项目(项目编号:023612511)
关键词
唐氏综合征
生化标记物
孕早期筛查
颈部透明带
Down＇s syndrome
Biochemical markers
First- trimester screening
Nuchal translucency
